Disclosed is a humanized anti-human α9-integrin antibody having improved activities and/or physical properties compared with a donor mouse anti-human α9-integrin antibody. Specifically disclosed are: a humanized anti-human α9-integrin antibody having a heavy-chain variable region comprising the amino acid sequence depicted in SEQ ID NO:11 and a light-chain variable region comprising the amino acid sequence depicted in SEQ ID NO:17； a humanized anti-human α9-integrin antibody having a heavy-chain variable region comprising the amino acid sequence depicted in SEQ ID NO:13 and a light-chain variable region comprising the amino acid sequence depicted in SEQ ID NO:17； and a humanized anti-human α9-integrin antibody having a heavy-chain variable region comprising the amino acid sequence depicted in SEQ ID NO:15 and a light-chain variable region comprising the amino acid sequence depicted in SEQ ID NO:9. Also disclosed is a means for preventing or treating a disease of which human α9-integrin is involved in the development of the disease condition, which utilizes the antibody.
